• About us
• Contact

Advertisement

Organisation › Details

Laboratoris Sanifit S. L.

Sanifit is a biopharmaceutical company focused on the development of SNF472. The company was founded in 2007 as a spin-off of the University of the Balearic Islands. SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing hemodialysis. Sanifit has completed phase 1a studies with healthy volunteers in 2014. It is currently concluding a phase Ib/IIa study in hemodialysis patients. Following this series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in ESRD and extend the orphan program in calciphylaxis into phase II/III clinical trials. *

 

	Start	2007-01-01 splitoff
	Group	Vifor Pharma (Group)
	Industry	cardiovascular drug
	Industry 2	SNF472 (Sanifit)
	Person	Perelló, Joan (Sanifit 201509 CEO)
	Region	Palma de Mallorca
	Country	Spain (España)
	City	07121 Palma de Mallorca, Islas Baleares
	Tel	+34-971-439-925
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Vifor Pharma (Group)

• [1] Invivo Partners. (3/5/24). "Press Release: Invivo Partners Is Preparing to Launch a €100M Invivo Ventures III Fund to Invest in Leading-edge Life Sciences". Barcelona....
• [2] Ysios Capital. (1/19/23). "Press Release: Ysios Capital Strengthens Its Team with Internal Promotions and a New Venture Partner". San Sebastián & Barcelona....
• [3] T-Knife Therapeutics, Inc.. (1/5/22). "Press Release: T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel". South San Francisco, CA & Paris....
• [4] Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen....
• [5] Vifor Pharma AG. (11/22/21). "Press Release: Vifor Pharma to Spearhead Development of Vascular Calcification Field, through Acquisition of Sanifit Therapeutics and Inositec AG". St. Gallen, Palma & Zurich....
• [6] Vifor Pharma AG. (11/09/20). "Press Release: Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications". St. Gallen & Uniondale, NY....
• [7] Vifor Pharma AG. (10/20/20). "Press Release: Vifor Pharma and Cara Therapeutics Sign US License Agreement for i.v. Korsuva to Treat Dialysis Patients with Pruritus". St. Gallen & Stamford, CT....
• [8] ChemoCentryx Inc.. (11/25/19). "Press Release: ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis". Mountain View, CA & St...
• [9] Evotec SE. (11/6/19). "Press Release: Evotec and Vifor Pharma Form Joint Venture for Early Development in Nephrology". Hamburg & St. Gallen....
• [10] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.